ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2013
Expression of angiopoietin-TIE system components in angiosarcoma.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies.Frontiers in oncology · 2025Pooled it
- Primary cardiac angiosarcoma: From pathogenesis to therapeutic strategies.Medical oncology (Northwood, London, England) · 2026Review
- Exosome therapeutics for non-small cell lung cancer tumorigenesis.Cancer cell international · 2024Review
- How we use angiopoietin-2 in the diagnosis and management of vascular anomalies.Pediatric blood & cancer · 2024Article
- Histological and immunohistochemical prognostic factors of primary angiosarcoma.Virchows Archiv : an international journal of pathology · 2023Article
- Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders.Drugs · 2021Review
- Eculizumab-Responsive Adult Onset Protein Losing Enteropathy, Caused by Germline CD55-Deficiency and Complicated by Aggressive Angiosarcoma.Journal of clinical immunology · 2021Article
- Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis.Histology and histopathology · 2021Review
- Review
- Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers.International journal of molecular sciences · 2020Review
- When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma.Journal of immunotherapy and precision oncology · 2020Review
- Evaluation of plasma angiopoietin-2 and vascular endothelial growth factor in healthy dogs and dogs with systemic inflammatory response syndrome or sepsis.Journal of veterinary internal medicine · 2019Article
- Evidence for critical role of Tie2/Ang1 interaction in metastatic oral cancer.Oncology letters · 2018Article
- Ang-1 and Ang-2 expression in angiomyolipoma and PEComa family tumors.Journal of orthopaedics · 2017Article
- Ang-2 but not Ang-1 expression in perivascular soft tissue tumors.Journal of orthopaedics · 2017Article
- Endothelial cell malignancies: new insights from the laboratory and clinic.NPJ precision oncology · 2017Article
- Tie2 Regulates Tumor Metastasis of Oral Squamous Cell Carcinomas.Journal of Cancer · 2016Article
- Tie-1: A potential target for anti-angiogenesis therapy.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Angiosarcoma is an aggressive malignancy of endothelial differentiation. Potential roles of the endothelial angiopoietin-tunica interna endothelial cell kinase (ANGPT-TIE) system in angiosarcoma diagnosis, pathogenesis, prognosis and treatment are undefined. To examine the expression and prognostic significance of angiopoietin-1, angiopoietin-2, TIE1 and TEK (TIE2) proteins in angiosarcoma, we immunohistochemically evaluated clinically annotated human angiosarcoma samples. Correlations of protein expression with overall survival and pathological features were explored. The cohort included 51 patients diagnosed with angiosarcoma at the age of 30-86 years (median 67). The 5-year overall survival was 45% with a median of 26 months. Moderate to strong expression of angiopoietin-1, TIE1 and TEK (TIE2) was identified in the majority of angiosarcomas and moderate to strong expression of angiopoietin-2 was observed in 42% of angiosarcomas. Increased angiopoietin-1 expression correlated with improved survival. Non-significant trends toward longer survival were also observed with increased TIE1 and TEK (TIE2) expression. Increased expression of angiopoietin-2, TIE1 and TEK (TIE2) was associated with vasoformative architecture. No differences in expression of these proteins were observed when patients were segregated by age, gender, presence or absence of metastases at diagnosis, primary tumor location, radiation association or the presence of necrosis. We conclude that components of the ANGPT-TIE system are commonly expressed in angiosarcomas. Reduced expression of these proteins is associated with non-vasoformative and clinically more aggressive lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.